Synovial Sarcoma clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • ACTengine® IMA203 Combined With mRNA-4203

    open to eligible people ages 18 years and up

    This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

    San Francisco, California and other locations

Our lead scientists for Synovial Sarcoma research studies include .